Monoclonal Gammopathy of Undetermined Significance

This is a term used for certain blood test results that show a type of protein called M protein. Doctors don't know if it's serious yet, so they monitor it. It's not the same as multiple myeloma, which is a more serious cancer.

Condition

What people with Monoclonal Gammopathy of Undetermined Significance report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Monoclonal Gammopathy of Undetermined Significance

What It Is

Monoclonal gammopathy of undetermined significance (MGUS) means a blood test has found a small amount of an abnormal antibody protein, called an M protein (monoclonal protein), without any sign that it is harming the body. Plasma cells in the bone marrow normally make many different antibodies to fight infection. In MGUS, one plasma cell or a related immune cell has multiplied into a group of identical cells, and they all make copies of the same antibody, which serves no useful purpose. MGUS causes no symptoms, and most people learn about it by chance, often from blood tests done for another reason. It matters because it is a precursor condition. Each year, about 1 in 100 people with the most common types develops a related blood cancer, such as multiple myeloma, or a related disorder called AL (light-chain) amyloidosis, in which the abnormal protein builds up in organs. Most people with MGUS never progress, which is why the usual approach is careful monitoring rather than treatment. The National Cancer Institute describes MGUS as not cancer, but able to become cancer. There are three main types, named for the protein involved. IgG and IgA MGUS (non-IgM MGUS) make up about 80% of cases and can lead to multiple myeloma. IgM MGUS can lead to Waldenström macroglobulinemia, a slow-growing lymphoma. Light-chain MGUS makes only fragments of antibody and carries a particular risk of amyloidosis and kidney problems.

Causes & Risk Factors

MGUS starts when genetic changes in a single plasma cell or B lymphocyte (the white blood cell that plasma cells develop from) allow it to multiply into an identical group, or clone. Researchers do not know what sets these changes off in most people, and nothing a person did is known to cause it. Age is the strongest risk factor. MGUS is found in about 3% of people over 50, 5% of people over 70 and 9% of people over 85. It is about twice as common in men as in women, and two to three times as common in Black Americans, in whom it also tends to appear at a younger age. Once MGUS is found, though, the chance of it progressing to myeloma appears similar across racial groups. Family history plays a role. Close relatives of someone with MGUS have about four times the usual chance of having MGUS themselves and about three times the usual chance of developing multiple myeloma, which points to shared genes or shared exposures. Most relatives are still never affected, and testing healthy people in the general population for MGUS is not recommended, because finding it has not been shown to improve outcomes and brings worry and follow-up tests. Obesity and smoking have been linked with a higher chance of MGUS progressing to myeloma, but these links come from observational studies and do not prove that changing them lowers an individual's risk.

How It's Diagnosed

MGUS is usually found through serum protein electrophoresis (SPEP), a blood test that separates the proteins in blood so that an M protein shows up as a narrow spike and can be measured. Two companion blood tests complete the picture. Immunofixation confirms that the protein is monoclonal and identifies its type, such as IgG or IgM. A serum free light chain test measures the two kinds of antibody fragments, kappa and lambda, and reports their ratio, since one type far outnumbering the other suggests a clone. Together these three tests find more than 97% of monoclonal gammopathies. A urine test is often added when results are abnormal. Some medicines that are themselves lab-made antibodies, such as infliximab (Remicade) or rituximab (Rituxan), can show up as a small M protein, so it helps to mention them. To be called MGUS, the M protein must be below 3 grams per deciliter (g/dL), abnormal plasma cells must make up less than 10% of the bone marrow, and there must be no damage the protein or cells could explain. Doctors check for that damage with a complete blood count to look for anemia and blood tests for calcium and kidney function. Higher protein levels, more marrow involvement or organ damage point instead to smoldering myeloma, multiple myeloma or another related condition. The test results also set a risk level. Three features raise the chance of progression: an M protein of 1.5 g/dL or higher, a type other than IgG, and an abnormal free light chain ratio. People with none of these have low-risk MGUS and can usually skip a bone marrow biopsy and bone imaging. With one or more, a hematologist (blood specialist) usually recommends a bone marrow biopsy and imaging, such as low-dose whole-body CT or MRI, to make sure myeloma is not already present. For IgM MGUS, a CT scan of the chest and abdomen is often preferred, to look for enlarged lymph nodes or organs that would suggest a lymphoma.

Treatment Options

MGUS itself is not treated. No approved medicine removes it or prevents it from progressing, and for people at low risk, the downsides of treatment would be unlikely to be worth it. Clinical trials are testing whether medicines or lifestyle changes can lower the risk for people with higher-risk MGUS. The standard of care is active monitoring: periodic blood tests and check-ups to spot change early. In observational studies, people whose MGUS was being monitored before it progressed to myeloma had fewer complications and lived longer than people whose myeloma was found only after it caused problems. Treatment becomes relevant in two situations. If MGUS progresses to multiple myeloma, Waldenström macroglobulinemia or AL amyloidosis, that disease is treated in its own right. And in a small number of people, the M protein damages an organ even though the abnormal cells remain few, most often the nerves, kidneys or skin. This is called monoclonal gammopathy of clinical significance (MGCS). It usually needs a biopsy of the affected organ to confirm, along with care from a specialist such as a neurologist or kidney doctor, and it may be treated with medicines aimed at the abnormal cells, sometimes similar to those used for myeloma, to protect the organ.

What to Expect

For most people, MGUS stays stable and never causes symptoms. The chance of progression is roughly 1% a year for IgG and IgA MGUS and about 1.5% a year for IgM MGUS. Over decades, that adds up: in a long-term Mayo Clinic study of more than 1,300 people with MGUS, about 1 in 10 had progressed after 10 years and nearly 1 in 5 after 20 years. Risk level matters. In the original risk model, about 5% of people with low-risk MGUS progressed within 20 years, and even in the high-risk group, roughly three in four had not progressed after 20 years once deaths from other causes were taken into account. The risk is highest in the first year after diagnosis and is lower when the M protein level stays steady. Follow-up is mostly blood tests. A first recheck is usually done about 6 months after diagnosis. If results are stable and the risk is low, testing can often be spaced out to every 2 to 3 years, or sooner if new symptoms appear. People with intermediate- or high-risk MGUS are usually checked every 6 months at first, then about once a year if things stay stable. For someone whose life expectancy is short because of other illnesses, routine monitoring may offer little benefit, and it is reasonable to discuss whether it is needed. MGUS does not limit work, exercise, diet or travel. Learning that you have a condition linked to cancer can still be unsettling, and the uncertainty of regular testing can weigh on people. Understanding your own risk level often makes the diagnosis easier to put in proportion.

When to Seek Help

Keep scheduled blood tests even when you feel well, since MGUS has no symptoms that warn of change. Contact your care team rather than waiting for the next planned test if you develop new bone pain, a fracture after a minor injury, unexplained tiredness, weight loss, night sweats or infections that keep coming back, which can be signs of progression to myeloma or lymphoma. Also report numbness, tingling or weakness that starts in the feet and spreads, swelling of the legs with foamy urine, increasing breathlessness, a changed voice or enlarged tongue, or bruising and bleeding more easily than usual. These can signal amyloidosis or damage to the nerves, kidneys or heart from the abnormal protein.

Questions to Ask Your Doctor

  1. 1.What type of MGUS do I have, and which risk group does it put me in?
  2. 2.Do I need a bone marrow biopsy or imaging, or is it safe to skip them?
  3. 3.How often should my blood be rechecked, and who will follow the results over the years?
  4. 4.Could any of my current symptoms or medical conditions be related to the M protein?
  5. 5.Should my close relatives be tested, and is there a clinical trial that would suit me?

Last reviewed • Oct 2026

Educational content, not medical advice.